drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T-cell)
drug_description
Genetically modified autologous T lymphocytes engineered to express a chimeric antigen receptor targeting Trop-2 (TACSTD2) for adoptive cell therapy in advanced head and neck cancers.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor specific for Trop-2 (TACSTD2). CAR binding to Trop-2 on tumor cells triggers CD3 zeta/costimulatory signaling, activating the T cells to release cytokines and mediate perforin/granzyme-dependent lysis of Trop-2-positive head and neck cancer cells.
drug_name
U87 autologous CAR T cells
nct_id_drug_ref
NCT06614686